Project title: CELL THERAPY FOR EXCITABLE TISSUE DISORDERS

Company name : GENEGRAFTS LTD.

TECHNOLOGICAL FIELD
Cell Therapy

KEY WORDS
Gene Therapy, Cell
Therapy, Cardiac Arrhythmias, Atrial Fibrillation, Parkinson's
Disease

PROJECT SUMMARY
GeneGrafts LTD is a biotechnology company developing proprietary
technology for modulating excitable tissues (e.g. Brain, Heart).
This new paradigm can be used for the treatment of various
diseases including Parkinson's disease and other neurological
disorders, and cardiac arrhythmias.

GeneGrafts is based in the Technological Incubator founded by the
Technion R&D Foundation Ltd. The company has raised seed funding
from the Office of the Chief Scientist of the Israeli Ministry of
Industry and Trade, 4 major Venture Capital funds and a large
international strategic partner, and began operations in November
2003.

MARKETS
More than 28 million people suffer from excitable tissue
disorders in the U.S. Excitable tissues consist of cells that can
be stimulated to create tiny electrical impulses or "action
potentials". Heart cells (cardiac myocytes), nerve cells
(neurons) and pancreatic cells are excitable. A disruption or
abnormality in the creation or conductance of electrical impulses
can lead to Cardiac arrhythmias; Parkinson's disease or epilepsy,
and Type 2 diabetes.
These disorders have a high impact on quality of life and
generate approximately $180 billion in direct and indirect
healthcare expenditures each year.

ENTREPRENEURS
Dr. Yair Feld - MD, Ph.D., CEO, has
conducted, in his Ph.D. thesis, the first feasibility experiments
using genetically engineered cell grafts to modify the
electrophysiological properties of excitable tissue on cultured
cardiomyocytes.
Prof. Lior Gepstein - MD, Ph.D., Head of the
Cardiovascular Research Laboratory, Department of Biophysics and
Physiology, The Bruce Rappaport Faculty of Medicine, Technion-
Israel Institute of Technology, and a cardiologist at Rambam
Medical Center.
Prof. Shimon Marom - MD, Ph.D., an expert in
molecular, cellular, and network aspects of excitable systems,
Director of the Bernard Katz Minerva Center for Cell Biophysics
at the Technion Faculty of Medicine.
Dr. Meira Melamed-Frank - Ph.D., an expert in molecular
biology and electrophysiology.

PROJECT STATUS
The Company commenced its development activities within the
incubator in 2003 and is currently carrying out development
trials with large animals.

COOPERATION REQUIRED
Seed investment and strategic partners.
---------------------------------------------------------------
E-MAIL: feld@genegrafts.com, WEB: www.genegrafts.com

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about